Diferencia entre revisiones de «Etomidate»

Sin resumen de edición
(Switch SMW query from broadtable to table format for better layout with TOC)
 
(No se muestran 33 ediciones intermedias de 11 usuarios)
Línea 1: Línea 1:
==[[RSI]]==
''See [[critical care quick reference]] for drug doses by weight.''
0.3 mg/kg bolus IV {Adult standard = 20mg)
==General==
*Type: [[Sedation|Sedative]]
*Dosage Forms: IV
*Common Trade Names: Amidate, Tomvi


==[[Procedural Sedation]]==
==Adult Dosing==
0.15 mg/kg bolus IV (Adult standard = 10mg)
===[[RSI]]===
*0.3mg/kg bolus IV  
*Average: 20mg
**Consider half-dose (0.15mg/kg) for obtunded patients


==Controversy==
===[[Procedural Sedation]]===
"The available evidence suggests that etomidate suppresses adrenal function transiently without
{{Procedure sedation etomidate}}
demonstrating a significant effect on mortality. However, no studies to date have been powered to detect a difference in hospital, ventilator, or ICU length of stay or in mortality."


==Source==
==Pediatric Dosing==
''See [[critical care quick reference]] for drug doses by weight.''


[[Category:Drugs]]
*Children < 10 years
**0.2-0.3 mg/kg IV
*Children > 10 years
**0.3 mg/kg IV
 
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*Lactation: etomidate is present in breast milk
*Renal Dosing
**Adult
*** Not defined however higher risk of toxicity with renal impairment
**Pediatric
*** Not defined however higher risk of toxicity with renal impairment
*Hepatic Dosing
**Adult
*** Not defined
**Pediatric
*** Not defined
 
==Contraindications==
*Allergy to class/drug
 
==Adverse Reactions==
*Myoclonus
*Nausea/Vomiting
*Pain at injection site
* apnea
===Controversy===
*May suppress adrenal function in critically ill patient
**"The available evidence suggests that etomidate suppresses adrenal function transiently without
demonstrating a significant effect on mortality. However, no studies to date have been powered to detect a difference in hospital, ventilator, or ICU length of stay or in mortality."<ref>*Hohl CM, Kelly-Smith CH,Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M.  The effect of a bolus dose of Etomidate on cortisol levels, mortality, and health services utilization: a systematic review.  Ann Emerg Med. 2010;56(2):105-113.</ref>
*Meta-analysis in 2023 showed increased mortality in critically ill patients
 
==Pharmacology==
*Half-life: 75 minutes
*Metabolism: Liver
*Excretion: Urine
*Mechanism of Action: GABA agonist
 
 
==Indications by Condition==
''The following table is automatically generated from disease/condition pages across WikEM.''
 
{{#ask:[[Has DrugName::Etomidate]]
|?Has Indication=Indication
|?Has Dose=Dose
|?Has Context=Context
|?Has Route=Route
|?Has Population=Population
|format=table
|headers=plain
|mainlabel=-
|sort=Has Indication
|limit=50
}}
 
==See Also==
 
==References==
<references/>
 
[[Category:Pharmacology]]
[[Category:Critical Care]]
 
Etomidate: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.

Revisión actual - 21:57 20 mar 2026

See critical care quick reference for drug doses by weight.

General

  • Type: Sedative
  • Dosage Forms: IV
  • Common Trade Names: Amidate, Tomvi

Adult Dosing

RSI

  • 0.3mg/kg bolus IV
  • Average: 20mg
    • Consider half-dose (0.15mg/kg) for obtunded patients

Procedural Sedation

  • 0.1mg/kg one time dosing
  • Max: 10mg
  • Minimal respiratory depression but decrease blood pressure and heart rate (alpha2 agonism)

Pediatric Dosing

See critical care quick reference for drug doses by weight.

  • Children < 10 years
    • 0.2-0.3 mg/kg IV
  • Children > 10 years
    • 0.3 mg/kg IV

Special Populations

  • Pregnancy Rating: C
  • Lactation: etomidate is present in breast milk
  • Renal Dosing
    • Adult
      • Not defined however higher risk of toxicity with renal impairment
    • Pediatric
      • Not defined however higher risk of toxicity with renal impairment
  • Hepatic Dosing
    • Adult
      • Not defined
    • Pediatric
      • Not defined

Contraindications

  • Allergy to class/drug

Adverse Reactions

  • Myoclonus
  • Nausea/Vomiting
  • Pain at injection site
  • apnea

Controversy

  • May suppress adrenal function in critically ill patient
    • "The available evidence suggests that etomidate suppresses adrenal function transiently without

demonstrating a significant effect on mortality. However, no studies to date have been powered to detect a difference in hospital, ventilator, or ICU length of stay or in mortality."[1]

  • Meta-analysis in 2023 showed increased mortality in critically ill patients

Pharmacology

  • Half-life: 75 minutes
  • Metabolism: Liver
  • Excretion: Urine
  • Mechanism of Action: GABA agonist


Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

IndicationDoseContextRoutePopulation
Procedural sedation0.15 mg/kgProcedural sedationIVAdult
Procedural sedation0.1-0.2 mg/kgProcedural sedation (solo)IVAdult
Rapid sequence intubation0.2-0.4 mg/kgInductionIVAdult

See Also

References

  1. ↑ *Hohl CM, Kelly-Smith CH,Yeung TC, Sweet DD, Doyle-Waters MM, Schulzer M. The effect of a bolus dose of Etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med. 2010;56(2):105-113.

Etomidate: Drug information. UpToDate. www.uptodate.com. Accessed April 2, 2019.

Obtenido de «https://www.wikem.org/w/index.php?title=Etomidate&oldid=387513»